LZYY(SH:603368) Zheng Quan Zhi Xing·2025-08-29 17:47Core Viewpoint - The board of directors of Guangxi Liuyuan Pharmaceutical Group Co., Ltd. held its 28th meeting, approving several key proposals including the half-year report and various governance changes aimed at enhancing operational efficiency and corporate governance [1][2][3]. Meeting Details - The board meeting was held on August 28, 2025, with all 7 directors present, ensuring compliance with legal and procedural requirements [1]. Financial Reports - The board approved the 2025 half-year report and its summary, with unanimous support from all directors [2]. - A special report on the use of raised funds was also approved, reflecting accurate management of funds during the reporting period [2]. Governance Changes - The board approved a proposal to change the registered capital and abolish the supervisory board, transferring some supervisory functions to the audit committee [3][4]. - A comprehensive revision of the company's articles of association was proposed to align with governance and regulatory requirements [3][4]. Risk Management - The board proposed purchasing liability insurance for directors and senior management to mitigate operational risks, with the proposal to be submitted to the shareholders' meeting due to conflicts of interest [7]. Incentive Plans - The board approved a draft for the 2025 stock option incentive plan aimed at attracting and retaining talent, which will also be submitted for shareholder approval [10][11]. - A management method for the stock option incentive plan was also approved, ensuring alignment with corporate goals [11][12]. Employee Stock Ownership Plan - The board approved a draft for the 2025 employee stock ownership plan to enhance employee engagement and align interests with shareholders, pending shareholder approval [15][16]. - A management method for the employee stock ownership plan was also established, ensuring compliance with relevant regulations [16][17]. Upcoming Meetings - The board scheduled the second extraordinary shareholders' meeting for September 15, 2025, to review the approved proposals [18].